New needle combo zaps returning liver tumors after failed chemo
NCT ID NCT07192172
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a special type of radiofrequency ablation using two cooled needles that also release saline to treat liver cancer that came back after chemoembolization. The goal was to see if this technique could better destroy the tumor and prevent it from growing back. One hundred adults with recurrent liver cancer were treated, and researchers tracked how many had tumor regrowth at the treatment site over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Twin Internally Cooled-Perfusion (TICP) electrodes for bipolar radiofrequency ablation
What this could lead to
If successful, this technique could offer a more effective way to destroy recurrent liver tumors after initial treatment, potentially improving local control and survival.
What could go wrong
This is a single-center, non-randomized study with only 100 participants. The results may not apply to all patients, and the procedure carries risks like bleeding or damage to nearby structures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul National University Hosptial
Seoul, Seoul, 03080, South Korea